IV Gamunex 10% — Competitive Intelligence Brief

IV Gamunex 10% (IV Gamunex 10%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunoglobulin. Area: Immunology.

phase 2 Immunoglobulin Immunology Small molecule

Target snapshot

IV Gamunex 10% (IV Gamunex 10%) — The Center for Rheumatic Disease, Allergy, & Immunology. Immunomodulation through the administration of intravenous immunoglobulin

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IV Gamunex 10% TARGET	IV Gamunex 10%	The Center for Rheumatic Disease, Allergy, & Immunology	phase 2	Immunoglobulin
HUMAN IMMUNOGLOBULIN G	HUMAN IMMUNOGLOBULIN G		marketed	Human Immunoglobulin G [EPC]		2006-01-01
IgPro20	IgPro20	CSL Behring	marketed	Immunoglobulin replacement therapy	Polyclonal IgG (multiple epitopes)
Gammaplex (5%)	Gammaplex (5%)	Bio Products Laboratory	marketed	Intravenous immunoglobulin (IVIG)	Fc receptors and complement system (indirect mechanism via antibody delivery)
MIS	MIS	Blood Transfusion Centre of Slovenia	marketed	Plasma-derived immunoglobulin preparation or blood product
Botulinum neurotoxin	Botulinum neurotoxin	University of Miami	marketed	Human Immunoglobulin G [EPC]
PRIVIGEN (CSL Behring)	PRIVIGEN (CSL Behring)	Hospices Civils de Lyon	marketed	Intravenous immunoglobulin (IVIg)	Fc receptors, complement system, pathogenic antigens and antibodies

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunoglobulin class)

1. The Center for Rheumatic Disease, Allergy, & Immunology · 1 drug in this class